United Imaging and the University of Tianjin have introduced uMR ShenGuan, an MRI-based brain-computer interface platform designed to monitor and influence neural activity. The launch took place in Tianjin before nearly 400 specialists. Billed as the first fully MRI-based BCI solution for research and clinical use, the platform was developed by Shanghai United Imaging Healthcare and Tianjin University. It has not undergone clinical trials or received regulatory approval.
Standard MRI scanners capture static images; uMR ShenGuan is designed to operate as a closed-loop system. It records and decodes brain signals, then applies targeted neuromodulation and measures the brain’s response. The goal is to make MRI an active tool for brain research and potentially therapy. G-MedTech reports that the platform combines signal acquisition with decoding, then adds neuromodulation and response assessment in a single process, unlike typical MRI applications.
At the inaugural National Conference on MRI-Brain-Computer Interface, the launch of uMR ShenGuan coincided with the creation of an new idea alliance for MRI-based BCI. The alliance signals a coordinated push for collaboration between industry and academia in China.
The platform runs on the uMR family of MRI machines, which support field strengths of 3.0, 5.0 and 9.4 teslas. Since October 2025, teams from United Imaging and the University of Tianjin have worked to integrate signal acquisition with hardware adaptation, then add image-guided neuromodulation. The system is intended to track changes linked to brain plasticity. Plans include multicenter studies and standardized protocols involving universities and hospitals, with regulatory agencies also involved. University news describes the work as part of a broader plan to build standardized BCI research platforms across China.
Developers claim the platform can achieve millisecond-level temporal resolution and sub-millimeter spatial accuracy. They also say it can compensate for magnetic field distortions caused by neural implants, a known challenge in MRI research. So far, those claims rest on internal data. The official release does not clarify whether millisecond timing refers to MRI alone or combined EEG-MRI setups, and independent benchmarks or peer-reviewed studies are unavailable. G-MedTech’s industry brief says uMR ShenGuan has no peer-reviewed publication or independent benchmarking; clinical trial data are also absent.
Here, ‘reading and modulating’ the brain does not mean accessing thoughts or memories. The system detects and decodes neural patterns tied to specific tasks or states, translating them into machine-readable instructions. The Chinese platform adds a feedback loop: after decoding, it delivers a targeted intervention and measures the brain’s reaction within the same technical setup. Modulation means influencing neural circuits with a stimulus, then observing the outcome through imaging and signal analysis. It does not mean controlling behavior.
Chinese regulatory authorities approved several BCI devices in August 2026, citing an NMPA decision dated August 19. The shift indicates that China’s BCI market is moving from laboratory research toward clinical application. uMR ShenGuan itself, but, has not received separate regulatory clearance or published clinical results.
Project leaders suggest possible uses in motor rehabilitation and neurological care, as well as psychiatry, ophthalmology and audiology. They also cite potential future uses in education and sports, with gaming among the other speculative applications. Sleep improvement and industrial safety are also mentioned. The system has not been tested in patient trials or produced peer-reviewed results, and it has no regulatory clearance. No hospitals or patient groups have been named, and there is no timeline for clinical rollout. University and industry sources identify stroke and trauma rehabilitation as basic clinical targets. They also cite neurocritical care and psychiatric interventions, with further interest in sensory and cognitive areas.
For now, uMR ShenGuan remains a research platform with ambitious claims but no independent validation. Its developers have yet to provide clinical data or open their results to outside review, leaving its promise of real-time, high-precision brain modulation unproven. China’s push in neurotechnology is clear; credibility will depend on transparent methods and reproducible results that meet global scientific standards.
